

## DAFTAR PUSTAKA

1. Sun H, Dickens BL, Chen M, Cook AR, Clapham HE. Estimating number of global importations of COVID-19 from Wuhan, risk of transmission outside mainland China and COVID-19 introduction index between countries outside mainland China. *BMC*. 2020.
2. Bernard SS, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, 2020. *Euro Surveill*. 2020;25(6).
3. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). *J Gen Intern Med*. 2020:1-5.
4. Gorbalenya AE, Baker SC, Baric RS, De Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. *Nature*. 2020.
5. Hageman JR. The Coronavirus Disease 2019 (COVID-19). *Pediatr Ann*. 2020;49(3):e99-e100.
6. Portal Resmi Provinsi Sumatera Barat. Informasi Covid-19 Provinsi Sumatera Barat 1 september 2020. 2020. <https://www.sumbarprov.go.id/homenews19381-info-covid-19-sumbar-selasa-1-september-2020.html> - Diakses tanggal 3 September 2020.
7. Kumar M, Kuroda K, Dhangar K, Mazumder P, Sonne C, Rinklebe J, et al. Potential emergence of antiviral-resistant pandemic viruses via environmental drug exposure of animal reservoirs. *Environ Sci Technol*. 2020;54(14):8503-8505.
8. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, et al. Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity Trial Results. *NEJM*. 2020:1-15.
9. Tan Q, Duan L, Ma YL, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. *Bioorg Chem*. 2020;104:104257.
10. Kementerian Kesehatan. Pedoman Pencegahan dan Pengendalian Corona Virus deases (Covid-19). *Kemenskes*. 2020;5:178. Diakses tanggal 5 September 2020.
11. Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) IDAI. Protokol tatalaksana Covid-19. 1st ed. 2020. <https://covid19.go.id/storage/app/media/Materi%20Edukasi/2020/Juli/Protokol%20Tatalaksana%20COVID-19%205OP%20FINAL.pdf> - Diakses tanggal 29 Oktober 2021.
12. WHO. The WHO Solidarity Trial for COVID-19 treatments officially launched in Indonesia. 2020. <https://www.who.int/indonesia/news/detail/24-04-2020-the-who-solidarity-trial-for-covid-19-treatments-officially-launched-in-indonesia> - Diakses tanggal 29 Oktober 2021.

13. Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, Ikatan Dokter Anak Indonesia. Pedoman tatalaksana COVID-19. 2nd ed. 2020.  
<https://www.papdi.or.id/pdfs/938/Pedoman%20Tatalaksana%20COVID-19%20edisi%202.pdf> - Diakses tanggal 29 Oktober 2021.
14. Kim J, Zhang J, Cha Y, Kolitz S, Funt J, Chong RE, et al. Coronavirus disease - 2019 (COVID-19) situation report – 94. ChemRxiv. 2020.
15. Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. *Curr Pharmacol Reports*. 2020;6(3):56-70.
16. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579.
17. Islam ABMMK, Khan MAAK. Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy. *Sci Rep*. 2020;10(1):1-16.
18. Worldometer. COVID-19 Coronavirus Pandemic. 2020.  
<https://www.worldometers.info/coronavirus/> - Diakses tanggal 29 desember 2020.
19. Portal Resmi Provinsi Sumatera Barat. Informasi Covid-19 Provinsi Sumatera Barat 28 Desember 2020. 2020.  
<https://www.sumbarprov.go.id/homenews19381-info-covid-19-sumbar-selasa-28-desember-2020.html> - Diakses tanggal 29 desember 2020.
20. Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The Natural History , Pathobiology , and Clinical Manifestations of SARS-CoV-2 Infections. *J Neuroimmune Pharmacol*. 2020;15(3):359-386.
21. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *cell*. 2020;181(2):281-292.e6.
22. Guo Y, Yan F, Feng T, Zhang L, Qin Q, Han W, et al. Switchable multi-wavelength thulium-doped fiber laser using four-mode fiber based sagnac loop filter. *IEEE Photonics J*. 2020;12(2):1-10.
23. Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. *Coronaviruses Methods Protoc*. 2015;1282(1):1-282.
24. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019- nCoV spike in the prefusion conformation. *Science*. 2020;367:1260–1263.
25. Schoeman D, Fielding BC, Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raudan F, et al. Coronavirus envelope protein: current knowledge. *Cell Res*. 2020;9(1):278-280.
26. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell Mol Immunol*. 2020;17(6):613-620.
27. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): scientific brief: SARS-CoV-2 and potential airborne

- transmission. 2020.  
[https://www.ncbi.nlm.nih.gov/books/NBK570442/pdf/Bookshelf\\_NBK570442.pdf](https://www.ncbi.nlm.nih.gov/books/NBK570442/pdf/Bookshelf_NBK570442.pdf) - Diakses tanggal 21 Oktober 2021.
28. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Natl Institutes Heal. 2019.  
<https://www.covid19treatmentguidelines.nih.gov/> - Diakses tanggal 31 Desember 2020.
  29. Wong MC, Cregeen SJJ, Ajami NJ. Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *Biorxiv*. 2020;2013.
  30. Heininger U. Severe acute respiratory syndrome coronavirus 2 vaccines: Setting expectations appropriately. *Pediatr Infect Dis J*. 2020:E123-E124.
  31. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med*. 2020;26:450-452.
  32. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*. 2020;367:1444–1448.
  33. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181:271–280.
  34. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020;9:386–389.
  35. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha\_ketoamide inhibitors. *Science*. 2020;368:409–412.
  36. Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. *Cell Res*. 2017;27(1):119-129.
  37. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci USA*. 2017;114:E7348-E7357.
  38. Walls AC, Xiong X, Park YJ, Tortorici MA, Snijder J, Quispe J, et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. *Cell*. 2019;176(5):1026-1039.e15.
  39. Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. *Nat Commun*. 2017;8:1-9.
  40. Fang L. Structure, function, and evolution of Coronavirus spike proteins. *Annu Rev Virol*. 2016;3:237–261.
  41. Rey F, Lok S. Common features of enveloped viruses and implications for immunogen design for next-generation vaccines. *Cell*. 2018;172:1319–1334.
  42. Shi P, Su Y, Li R, Liang Z, Dong S, Huang J. PEDV nsp16 negatively regulates innate immunity to promote viral proliferation. *Virus Res*. 2019;265:57-66.
  43. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. *Antivir Res*. 2018;149:58-74.



44. Beachboard DC, Anderson-Daniels JM Denison MR. Mutations across murine hepatitis virus nsp4 alter virus fitness and membrane modifications. *J Virol.* 2015;89(4):2080-2089.
45. Zhu X, Fang L, Wang D, Yang Y, Chen J, Ye X, et al. Porcine deltacoronavirus nsp5 inhibits interferon-beta production through the cleavage of NEMO. *Virology.* 2017a;502:33-38.
46. Zhu X, Fang L, Wang D, Yang Y, Chen J, Ye X, et al. Porcine deltacoronavirus nsp5 antagonizes type I interferon signaling by cleaving STAT2. *J Virol.* 2017b;91(10):e00003-17.
47. Kirchdoerfer RN Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nat Commun.* 2019;10(1):2342.
48. Zeng Z, Deng F, Shi K, Ye G, Wang G, Fang L, et al. Dimerization of coronavirus nsp9 with diverse modes enhances its nucleic acid binding affinity. *J Virol.* 2018;92(17):e00692-18.
49. Dedeji AO, Lazarus H. Biochemical characterization of Middle East respiratory syndrome coronavirus helicase. *mSphere.* 2016;1:5.
50. Hao W, Wojdyla JA, Zhao R, Han R, Das R, Zlatev I, et al. Crystal structure of Middle East respiratory syndrome coronavirus helicase. *PLOS Pathog.* 2017;13(6):e1006474.
51. Jia Z, Yan L, Ren Z, Wu L, Wang J, Guo J, et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. *Nucleic Acids Res.* 2019;47(12):6538-6550.
52. Deng X, Hackbart M, Mettelman RC, O'Brien A, Mielech AM, Yi G, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. *Proc Natl Acad Sci USA.* 2017;114(21):E4251-E4260.
53. Zhang L, Li L, Yan L, Ming Z, Jia Z, Lou Z, et al. Structural and biochemical characterization of endoribonuclease Nsp15 encoded by middle east respiratory syndrome coronavirus. *J Virol.* 2018;92(22):e00893-18.
54. Fung TS, Liu DX. Post-translational modifications of coronavirus proteins: roles and function. *Futur Virol.* 2018;13:405–430914–921.
55. Zheng J, Yamada Y, Fung TS, Huang M, Chia R, Liu DX. Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture. *Virology.* 2018;513:65–74.
56. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network\_based drug repurposing for novel coronavirus 2019-nCoV/SARS\_CoV-2. *Cell Discov.* 2020;6:14.
57. Shuai Ji, Zhi Z, Yuanyuan S, Tengfei Z, Li S. Coral gasdermin triggers pyroptosis. *Sci Immunol.* 2020;5(54):eabd2591.
58. Storm C, Fajgenbaum DC, June CH. Cytokine Storm. 2020:2255-2273.
59. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395:497–506.
60. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77:1-9.
61. Baig MS, Alagumuthu M, Rajpoot S, Saqib U. Identification of a potential

- peptide inhibitor of SARS - CoV - 2 targeting its entry into the host cells. *Drugs R D*. 2020;20(3):161-169.
62. Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al. Aspirin use Is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19. *Anesth Analg*. 2020.
  63. Eliezer M, Hautefort C, Hamel AL, Verillaud B, Herman P, Houdart E, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. *JAMA Otolaryngol Head Neck Surg*. 2020;146(7):674-675.
  64. Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. *Emerg Infect Dis CDC*. 2020;26(8):1920-1922.
  65. Martinez-Rojas MA, Vega-Vega O, Bobadilla XNA. Is the kidney a target of SARS-CoV-2?. *Am J Physiol - Ren Physiol*. 2020;318(6):F1454-F1462.
  66. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int*. 2020;98(1):219-227.
  67. Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. *Nature*. 2020;2.
  68. Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. *Int J Soc Psychiatry*. 2020;66(4):317-320.
  69. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *The Lancet Psychiatry*. 2020;7(7):611-627.
  70. Federico A. Brain awareness week, CoVID-19 infection and neurological sciences. *Neurol Sci*. 2020;41:747-748.
  71. Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. *Dermatol Ther*. 2020;33(4).
  72. Trypsteen W, Van Cleemput J, van Snippenberg W, Gerlo S, Vandekerckhove L. On the whereabouts of SARS-CoV-2 in the human body: A systematic review. *PLoS Pathog*. 2020;16(10):1-26.
  73. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. *NEJM*. 2020;120(1):26-28.
  74. Alvi MM, Sivasankaran S, Singh M. Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19. *J Drug Target*. 2020;28(7-8):1-13.
  75. Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia Ikatan Dokter Anak Indonesia. *PEDOMAN TATALAKSANA COVID-19*. 3rd ed.; 2020.  
<https://www.papdi.or.id/pdfs/983/Buku%20Pedoman%20Tatalaksana%20COVID-19%205OP%20Edisi%203%202020.pdf> - Diakses tanggal 21

Oktober 2021.

76. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): how to protect yourself & others. 2020a. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention-H.pdf> - Diakses tanggal 31 Desember 2020.
77. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): infection control guidance for healthcare professionals about coronavirus (COVID-19). 2020b. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html> - Diakses tanggal 31 desember 2020.
78. Katzung BG, Masters SB, Trevor AJ. Farmakologi dasar dan klinik. 12th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2010. p.861-862.
79. Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaeei M, Eslami M. A global treatments for coronaviruses including COVID-19. *J Cell Physiol.* 2020;235(12):9133-9142.
80. Indari O, Jakhmola S, Manivannan E, Jha HC. An update on antiviral therapy against SARS-CoV-2: how far have we come?. *Front Pharmacol.* 2021;12(March):1-15.
81. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. *Antiviral Res.* 2018;153:85–94.
82. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. *Pharmacol Ther.* 2020;209:107512.
83. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. *MedRxiv.* 2020.
84. Fang QQ, Huang WJ, Li XY, Cheng YH, Tan MJ, Liu J, et al. Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. *Virology.* 2020;545:1-9.
85. Ying-Hui J, Qing-Yuan Z, Zhi-Yong P, Xue-Qun R, Xun-Tao Y, Lin C, et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). *Med J Chinese People's Lib Army.* 2020;45(10):1003-1029.
86. Driouch JS, Cochin M, Lingas G, Laprie C, Coutard B, Guedj J, et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. *Nat Commun.* 2021;12(1):1-13.
87. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *NEJM.* 2020;382:1787-1799.
88. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. *J Korean Med Sci.* 2020;35(6):e79.
89. Nutho B, Mahalapbutr P, Hengphasatporn K, Pattarangoon NC, Simanon N, Shigeta Y, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. *Biochemistry.* 2020;59(18):1769-1779.
90. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of



- eosinophil may predict the outcome of COVID-19 progression. *Int J Infect Dis.* 2020;95:183–191.
91. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269–271.
  92. Brown AJ, Won JJ, Graham RL, Dinno KH, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. *Antiviral Res.* 2019;169:104541.
  93. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. *NEJM.* 2020;383(19):1813-1826.
  94. Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med.* 2017;9(396):eaal3653.
  95. Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. *Antiviral Res.* 2018;149:143–149.
  96. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med.* 2020;180(10):1345-1355.
  97. Arifin Z, Fatmawati BR, Isstianah I, Zuliardi. Characteristics of patients with corona virus disease. 2021;11:587-594.
  98. Global Health 5050. The sex, gender, and COVID-19 project. 2021. <https://globalhealth5050.org/the-sex-gender-and-covid-19-project/> - Diakses Februari 2021.
  99. Carozzi F. Urban density and Covid-19. *SSRN Electron J.* 2021: 1-37.
  100. Duhri AP, Jabbar R, Yunus N. Karakteristik pasien konfirmasi COVID-19 di RSUD Lamadukkelleng Kabupaten Wajo (tinjauan pasien periode Maret-September 2020). *Media Kesehat Politek Kesehat Makassar.* 2020; 15(2): 319-26.
  101. Klein SL, Huber S. Sex differences in susceptibility to viral infection. In: *Sex Hormones and Immunity to Infection.* 2010; 30: 93-122.
  102. Nugroho BP. Karakteristik klinis, radiologis, laboratorium dan derajat klinis COVID-19 di RS darurat penanggulangan COVID19 wisma atlet jakarta: A cohort retrospective study = clinical characteristics, radiological finding, laboratory profile, and severity of COVID-19. Program Studi Pulmonologi & Ilmu Kedokteran Respirasi. 2020.
  103. Verdecchia P, Cavallini C, Spanevello A, Angeli F. COVID-19: ACE2centric infective disease?. *AHA.* 2020; 76(2): 294-9.
  104. Kang IS, Kong KA. Body mass index and severity/fatality from coronavirus disease 2019: A nationwide epidemiological study in Korea. *PLoS One.* 2021; 16(6): 1-13.
  105. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA et al. Repurposed antiviral drugs for Covid-19 — Interim WHO solidarity trial results. *NEJM.* 2021;384(6):497-511.
  106. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-

- Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2021;27(1):19-27.
107. Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia IDAI. Pedoman Pencegahan dan Pengendalian Coronavirus disease. *Kemenkes.* 2020.  
[https://covid19.go.id/storage/app/media/Protokol/2020/Juli/REV-05\\_Pedoman\\_P2\\_COVID-19\\_13\\_Juli\\_2020.pdf](https://covid19.go.id/storage/app/media/Protokol/2020/Juli/REV-05_Pedoman_P2_COVID-19_13_Juli_2020.pdf) - Diakses tanggal 29 Oktober 2021.
108. Luo H, Liu S, Wang Y, et al. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: a retrospective, multicentre cohort study. *BMJ Open.* 2020;10(10):e039887.
109. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends.* 2020;14(1):69-71.

